<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">821</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2016-15-3-47-54</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">EVALUATION OF BIOMODIFIED L-ASPARAGINASE WAS79 SIDE EFFECTS IN CHRONIC EXPERIMENT ON RABBITS</article-title><trans-title-group xml:lang="ru"><trans-title>ОЦЕНКА ПОБОЧНЫХ ЭФФЕКТОВ БИОМОДИФИЦИРОВАННОй L-АСПАРАГИНАЗЫ WAS79 В ХРОНИЧЕСКОМ ЭКСПЕРИМЕНТЕ НА КРОЛИКАХ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pereverzeva</surname><given-names>E. R.</given-names></name><name xml:lang="ru"><surname>Переверзева</surname><given-names>Элеонора Рафаиловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>pereverzeva-ella@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Treschalin</surname><given-names>I. D.</given-names></name><name xml:lang="ru"><surname>Трещалин</surname><given-names>И. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Treschalin</surname><given-names>M. I.</given-names></name><name xml:lang="ru"><surname>Трещалин</surname><given-names>М. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Voznyakovskaya</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Возняковская</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pereverzeva</surname><given-names>T. B.</given-names></name><name xml:lang="ru"><surname>Переверзева</surname><given-names>Т. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Eremkin</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Еремкин</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bulushova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Булушова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sannikova</surname><given-names>E. P.</given-names></name><name xml:lang="ru"><surname>Санникова</surname><given-names>Е. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><institution>ФГБНУ «Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе»</institution></aff><aff id="aff2"><institution>ФГУП«Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов»</institution></aff><pub-date date-type="pub" iso-8601-date="2016-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2016</year></pub-date><volume>15</volume><issue>3</issue><fpage>47</fpage><lpage>54</lpage><history><date date-type="received" iso-8601-date="2018-04-10"><day>10</day><month>04</month><year>2018</year></date></history><permissions/><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/821">https://bioterapevt.abvpress.ru/jour/article/view/821</self-uri><abstract xml:lang="en"><p>Objective. The aim of the study was to research the toxicity of L-asparaginase Was79 in rabbits. Materials and methods. Chronic toxicity of L-asparaginase Was79, obtained by modification of native enzyme Wolinella succinogenes in Research Institute of Genetics and Selection, was performed in male and female Russian chinchilla rabbits. L-asparaginase was injected intravenously at the 1 and 5 therapeutic dose (15 x 100 IU/kg or 15 x 500 IU/kg with 24-h interval). The following parameters were tested: body mass, clinical and biochemical blood tests, urinalysis, electrocardiography, pathomorphological evaluation of internal organs. Resutls. The results of the study suggest that the treatment with L-asparaginase Was79 does not influence on the function of heart and kidneys, but damages their structure. Loss in body mass, diarrhea and alteration of stomach and intestine mucosa could be interpreted as evidence of gastrointestinal toxicity. Hematological toxicity was exhibited as a decrease of total leukocyte count, lymphocyte and neutrophils count level in peripheral blood and atrophy of lymphoid tissue of the spleen, thymus and lymph nodes. Elevation of total and direct bilirubin in serum and histopathological findings in liver were found in groups treated with both high and low doses of Was79. Conclusion. Most of these abnormalities were reversible and dose-dependent.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="ru"><kwd>L-аспарагиназа</kwd><kwd>Wolinella succinogenes</kwd><kwd>хроническая токсичность</kwd><kwd>кролики</kwd><kwd>L-asparaginase</kwd><kwd>Wolinella succinogenes</kwd><kwd>chronic toxicity</kwd><kwd>rabbits</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Chan W.K., Lorenzi Ph. L., Anishkin A. et al. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood 2014; 123(23): 3596-606. DOI: 10.1182/blood-2013-10-535112. PMID: 24659632.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Covinia D., Tarditob S., Bussolatib O. et al. Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat Antkancer Drug Discov 2012; 7(1): 4-13. PMID: 21854356.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Duval M., Suciu S., Ferster A. et al. Comparison of Escherichia coli asparaginase with Erwinia asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trial. Blood 2002; 99(8): 2734-9. PMID: 11929760.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ollenschläger G., Roth E., Linkesch W. et al. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest1988; 18(5): 512-6. PMID: 3147904.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Reinert R.B., Oberle L.M., Wek S.A. et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 2006; 281(42): 31222-33. DOI: 10.1074/jbc.M604511200. PMID: 16931516.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bendich A., Kafkewitz D., Abuchowski A., Davis F.F. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice. Clin Exp Immunol 1982; 48(1): 273-8. PMID: 7044632.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Distasio J.A., Salazar A.M., Nadji M., Durden D.L. Glutaminase-free asparaginase from Vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int J Cancer 1982; 30(3): 343-7.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Durden D.L., Distasio J.A. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Res 1980; 40(4): 1125-9. PMID: 6986981.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Villa P., Corada M., Bartosek I. L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes. Toxicol Lett 1986; 32(3): 235-41. PMID: 3535170.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Покровский В.С. Новые подходы к созданию и экспериментальному изучению препаратов на основе противоопухолевых ферментов. Дис.. д-ра. мед. наук. М., 2015.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Покровский В.С., Залунин И.А., Константинова Г.Е. и др. Гибридный белок на основе L-аспарагиназы Wolinella succinogenes, штамм Escherichia coli - продуцент гибридного белка (варианты) и способ получения гибридного белка, обладающего противоопухолевой активностью. Патент РФ № 2562166 от 09.10.2014.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (Council of Europe, ETS No. 123). 1986.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Freireich E.J., Gehan E.A., Rall D.P. et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50(4): 219-44. PMID: 4957125.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Руководство по проведению доклинических исследований лекарственных средств. Под ред. А.Н. Миронова. М., 2012. C. 13-24.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>FDA. Erwinaze. Pharmacology review. Application № 125359. Approval date: 10/27/2011. URL: http://www.accessdata. fda.gov/drugsatfda_docs/nda/2011/1253590rig1s000PharmR.pdf</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Avramis V.I., Tiwari P.N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 2006; 1(3): 241-54. PMID: 17717965.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>FDA. Erwinaze. Clinical review. Application № 125359. Approval date: 11/18/2011. URL: http://www.accessdata. fda.gov/drugsatfda_docs/nda/2011/1253590rig1s000MedR.pdf</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Мedicines evaluation board. Public assessment report. Erwinase, powder for solution for injection 10,000 IU/vial. Procedure number L/H/3194/001/MR. September 2015, p. 1 - 17(5-6). URL: http://db.cbg-meb.nl/Pars/h16986.pdf</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Product Information. Elspar (asparaginase). Merck &amp; Co, Inc., West Point, PA.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Health Products Regulatory Authority. CRN 2126255. Erwinase 10,000 units powder for solution for injection. Date printed 10/07/2014. URL: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1020-002-001_10072014123107.pdf</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lavine R.L., Dicintio D.M. L-Asparaginase-induced diabetes mellitus in rabbits. Diabetes 1980; 29(7): 528-31. PMID: 6991339.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Plourde P.V., Jeha S., Hijiya N. et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer 2014; 61(7): 1232-8. DOI: 10.1002/pbc.24938. PMID: 24436152.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Chisari F.V., Hochstein H.D., Kirschstein R.L., Seligmann E.B. Parathyroid necrosis and hypocalcemic tetany induced in rabbits by L-asparaginase. Am J Pathol 1972; 68(3): 461-8. PMID: 5054253.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Pratt C.B., Johnson W.W. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer 1971; 28(2): 361-4. PMID: 5109448.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Raetz E.A., Salzer W.L. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010; 32(7): 554-63. DOI: 10.1097/ MPH.0b013e3181e6f003.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Storti E., Quaglino D. Dysmetabolic and neurologic complications in leukemic patients treated with L-asparaginase. Recent Results Cancer Res 1970; 33: 344-9. PMID: 5292723.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Haskel C.M., Canellos G.P, Leventhal B.G. et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969; 281(19): 1028-34. DOI: 10.1056/NEJM196911062811902. PMID: 4898857.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Fragasso G., Pastore M.R., Vicari A. et al. Myocardial infarction in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. Am J Hematol 1995; 48(2): 136-7. PMID: 7847336.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Keung Y.K., Rizk R., Wu X.Y., Cobos E. Drug-induced hypertriglyceridemia with and without pancreatitis. South Med J 1999; 92(9): 912-14. PMID: 10498170.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Priest J.R., Ramsay N.K.C., Steinherz P.G. et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100(6): 984-9. PMID: 6953221.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Переверзева Э.Р., Трещалин И.Д., Возняковская Е.В. и др. Токсикологическая характеристика биомодифици-рованного ферментного препарата - L-аспарагиназы Was79. Российский биотерапевтический журнал 2015; 14(4): 53-8.</mixed-citation></ref></ref-list></back></article>
